Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial In men with prostate cancer, bicalutamide monotherapy increases bone mineral ...

Please provide your email address to receive an email when new articles are posted on . The oral androgen receptor inhibitor enzalutamide significantly reduced the risk for prostate cancer progression ...

Combined modality therapy for stage II and stage III pancreatic carcinoma. Patients with progressive prostate cancer were treated with bicalutamide 200 mg daily. Before treatment, patients' tumors ...

Treatment with Xtandi reduced the risk of progression by 76 percent compared with bicalutamide in men with castration-resistant prostate cancer, according to topline results from the phase 2 STRIVE ...

April 15, 2005 — Tamoxifen can reduce the breast pain and gynecomastia associated with bicalutamide, according to the results of a randomized study published in the April 14 Early Online Publication ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — The addition of bicalutamide to radiation therapy significantly improved OS and freedom from ...

Ad5-prostate-specific enhancer (PSE)/probasin promoter (PBN) E1A-AR and Ad5 PSE/PBN-E1A-ARC685Y were generated using Ad-Easy system (Stratagene, La Jolla, CA, USA). The E1A-AR chimera includes ...

Review the side-effects of Bicalutamide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Advanced Prostate Cancer May Respond to Bicalutamide-Everolimus Combo In a small study, 75% of men with castration-resistant prostate cancer experienced a 30% or greater decline in PSA from baseline.

Bicalutamide (Bical (50 mg)) is a non-steroidal anti-androgen, prescribed for prostate cancer. It blocks testosterone action. The information provided on this page is intended to serve as a ...

Dublin, Dec. 07, 2021 (GLOBE NEWSWIRE) -- The "Research Report on China's Bicalutamide Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering. Bicalutamide, originally developed ...